Vasoserc Duo
Vasoserc DuoVasoserc Duo is a medicine recommended for illness and Meniere's syndrome, which is manifested by dizziness, sometimes accompanied by nausea and vomiting, hearing loss, and tinnitus. It can also be used to treat symptoms of vestibular dizziness of various origins. Read more about the drug and the features of the application in the instructions.
Indications for use (instruction): Vasoserc Duo
Meniere's disease and syndrome, characterized by three main symptoms:
- dizziness, which is sometimes accompanied by nausea and vomiting;
- hearing loss (hearing loss);
- tinnitus.
Symptomatic treatment of vestibular dizziness of various origins.
How to use
The daily dose for adults is 24–48 mg, evenly distributed for administration during the day, 1 tablet 2 times a day.
The drug is preferably taken with food or for a short period of time after a meal. The dose should be selected individually depending on the effect. Symptom relief is sometimes observed only after 2–3 weeks of treatment. The best results are achieved when taking the drug for several months. There is evidence that the appointment of treatment at the beginning of the disease prevents its progression and/or hearing loss in the later stages.
Elderly patients
Although at the moment the data of clinical studies in this group of patients are limited, the experience of using the drug in the post-registration period suggests that dose adjustment in this patient population is not necessary.
Renal failure
No special clinical trials were performed in this group of patients, but dose adjustment is not required in accordance with the experience of post-registration use.
Liver failure
No special clinical trials were performed in this group of patients, but dose adjustment is not required in accordance with the experience of post-registration use.
Children.
Due to the lack of data on the safety and effectiveness of the use of the drug, Vazoserk is not recommended for children (under the age of 18 years).
Contraindications
Hypersensitivity to any of the components of the drug.
Pheochromocytoma.
Composition
Active ingredient: betahistine;
1 tablet contains 24 mg betahistine dihydrochloride
Excipients: mannitol (E 421), microcrystalline cellulose, polyplasdone XL, citric acid monohydrate, talc, colloidal silicon dioxide, stearic acid.
Release form
15 tablets in a blister, 2 blisters in a cardboard box.
Dosage form. Pills.
Basic physical and chemical properties: white round tablets with a fault line on one side.
Storage conditions
Store at a temperature not exceeding 25 ° C in a place protected from moisture and not suitable for children.
Manufacturer
Abdi Ibrahim Ilach Sanai ve Tijaret A.Sh., Orhan Ghazi Mahalleshi Tunc Jaddesi No.3, Esenyurt/Istanbul, Turkey.
Registration certificate
No. 1401 dated 07/27/2018.
Registration certificate UA/3098/01/03.